Oppenheimer & Co’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-5,500
| Closed | -$468K | – | 1436 |
|
|
2020
Q3 | $468K | Sell |
5,500
-5,000
| -48% | -$253K | 0.01% | 832 |
|
|
2020
Q2 | $372K | Buy |
+10,500
| New | +$307K | 0.01% | 893 |
|
|
2017
Q1 | – | Sell |
-32,770
| Closed | -$120K | – | 1372 |
|
|
2016
Q4 | $120K | Hold |
32,770
| – | – | ﹤0.01% | 1221 |
|
|
2016
Q3 | $107K | Buy |
32,770
+5,000
| +18% | +$14K | ﹤0.01% | 1210 |
|
|
2016
Q2 | $64K | Sell |
27,770
-5,250
| -16% | -$17.5K | ﹤0.01% | 1186 |
|
|
2016
Q1 | $83K | Sell |
33,020
-3,750
| -10% | -$8.43K | ﹤0.01% | 1190 |
|
|
2015
Q4 | $113K | Buy |
36,770
+10,000
| +37% | +$27.9K | ﹤0.01% | 1200 |
|
|
2015
Q3 | $46K | Sell |
26,770
-66,056
| -71% | -$169K | ﹤0.01% | 1307 |
|
|
2015
Q2 | $377K | Sell |
92,826
-36,178
| -28% | -$148K | 0.01% | 1004 |
|
|
2015
Q1 | $494K | Sell |
129,004
-42,544
| -25% | -$185K | 0.01% | 872 |
|
|
2014
Q4 | $824K | Buy |
171,548
+38,388
| +29% | +$152K | 0.02% | 672 |
|
|
2014
Q3 | $495K | Buy |
133,160
+28,350
| +27% | +$95.8K | 0.01% | 856 |
|
|
2014
Q2 | $382K | Buy |
104,810
+11,600
| +12% | +$42.6K | 0.01% | 952 |
|
|
2014
Q1 | $392K | Buy |
93,210
+6,840
| +8% | +$33.9K | 0.01% | 926 |
|
|
2013
Q4 | $398K | Buy |
86,370
+18,200
| +27% | +$81K | 0.01% | 906 |
|
|
2013
Q3 | $422K | Sell |
68,170
-22,150
| -25% | -$128K | 0.01% | 825 |
|
|
2013
Q2 | $492K | Buy |
+90,320
| New | +$297K | 0.02% | 724 |
|
Oppenheimer & Co's IMMU Position: Q4 2020 in Review
Oppenheimer & Co sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 5,500 shares — an estimated $468K sold.
Oppenheimer & Co first reported a position in IMMU in Q2 2013 and held it in 17 quarters. The position peaked at $824K in Q4 2014. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Oppenheimer & Co reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Oppenheimer & Co sold 5,500 Immunomedics Inc shares in Q4 2020, an estimated $468K.
- Oppenheimer & Co first reported a position in Immunomedics Inc in Q2 2013 and held it in 17 quarters.
- Oppenheimer & Co's Immunomedics Inc position peaked at $824K in Q4 2014.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Oppenheimer & Co's 13F filing for Q4 2020, filed 11 Feb 2021.